NCT-547 has significant anti-tumor activity when used in combination with trastuzumab in trastuzumab-resistant cell lines by promoting the degradation of both p95HER2 and full-length HER2 as well as disrupting the HER2 family members’ dimerization [194]. Here, ERBB2 is linked to neoplasm.